Charalambos Andreadis, MD
University of California, San Francisco · Theagenio Cancer Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charalambos Andreadis, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:46 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02109627 · Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AMLC. Babis Andreadis · terminated · Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph2NCT01555541 · Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaC. Babis Andreadis · completed · Diffuse Large Cell Lymphoma Relapsed/Refractory · principal investigator
- Ph2NCT01301248 · Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and NeckTheagenio Cancer Hospital · unknown · Head and Neck Neoplasms, AJCC Stage III/IV · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.